5 results about "Glypican 3" patented technology

Radiopharmaceuticals and conjugates targeting GPC3, as well as their compositions and uses, are provided herein. In one embodiment, a conjugate comprising a peptide having avidity to GPC3 and a metal chelating agent configured to bind to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. The conjugate described herein may further comprise a radionuclide. In one embodiment, a radiopharmaceutical comprising a peptide and a metal chelating agent binding to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. Methods for treating cancer by administering the radiopharmaceuticals, conjugates, and compositions thereof are further provided herein.

Described herein are anti-Glypican 3 (GPC3) antibodies and binding proteins including such binding domains, as well as nucleic acids encoding the same. The disclosure also features methods of using such antibodies, antigen-binding fragments, binding proteins, and nucleic acid to treat various diseases, such as cancer (e.g., HCC).

The application relates to the technical field of biological medicine, in particular to an anti-Glypican 3 antibody and application thereof, the anti-Glypican 3 antibody is coded as B6 and B51, the anti-Glypican 3 antibody comprises a heavy chain variable region, the heavy chain variable region of the anti-Glypican 3 antibody comprises CDR-H1 with an amino acid sequence as shown in SEQ ID No. 1, CDR-H2 as shown in SEQ ID No. 2 and CDR-H3 as shown in SEQ ID No. 3. The anti-Glypican 3 antibody has high affinity and specificity, can effectively target tumor antigen Glypican 3, a chimeric antigen receptor is prepared by using the anti-Glypican 3 antibody, and a chimeric antigen receptor cell is further prepared, the chimeric antigen receptor cell can efficiently kill tumor cells and has high specificity.

This disclosure provides anti-GPC3 antibodies, including murine antibodies, humanized antibodies, and those with further optimized CDR sequences. The newly disclosed antibodies exhibited higher cell-based binding efficiency than the leading anti-GPC3 antibody candidate under clinical development.